A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

ConditionFollicular Lymphoma

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

About this trial

The purpose of this study is to characterise the long-term safety of lisocabtagene maraleucel, focusing on patients treated in the approved follicular lymphoma (FL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities

Eligibility criteria

Qualifiers

None

Disqualifiers

Participants known to be participating in investigational studies at the time of liso-cel, infusion

Participants treated with liso-cel for the treatment of R/R FL Grade 3b

Participants treated with non-conforming chimeric antigen receptor (CAR) T-cell product

Trial design

Treatments tested in this trial

Lisocabtagene maraleucel

Treatment groups

300 Participants

are divided into 1 treatment group

Sponsors and collaborators

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Lead sponsor

Source ClinicalTrials.gov